INSTRUCTIONS Management of patients with Parkinson disease
* To take the test online, go to our secure website at http://www.nursingcenter.com/ce/NP.
* On the print form, record your answers in the test answer section of the CE enrollment form on page 44. Each question has only one correct answer. You may make copies of these forms.
* Complete the registration information and course evaluation. Mail the completed form and registration fee of $24.95 to: Lippincott Williams & Wilkins, CE Group, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
* You will receive your CE certificate of earned contact hours and an answer key to review your results.There is no minimum passing grade.
* Registration deadline is October 31, 2015.
DISCOUNTS and CUSTOMER SERVICE
* Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together and deduct $0.95 from the price of each test.
* We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call 1-800-787-8985 for details.
Lippincott Williams & Wilkins, publisher of The Nurse Practitioner journal, will award 2.5 contact hours for this continuing nursing education activity.
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.5 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #50-1223.
Your certificate is valid in all states. This activity has been assigned 1.5 pharmacology credits.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
Management of patients with Parkinson disease
General Purpose: The purpose of this learning activity is to provide information about PD and its management. Learning Objectives: After reading this article and taking the test, the learner will be able to: 1. Discuss the incidence, pathophysiology, clinical manifestations, and diagnosis of PD. 2. Describe pharmacologic and nonpharmacologic management strategies for PD.
1. What percentage of patients is unable to live at home 10 years after PD diagnosis?
a. more than 75%
d. less than 10%
2. The most characteristic pathologic feature of PD is the
a. development of concentric hyaline inclusions (Lewy bodies) found in cytoplasm.
b. loss of dopamine-containing neurons in the substantia nigra pars compacta.
c. degeneration of serotonergic neurons.
d. degeneration of noradrenergic neurons.
3. Potential risk factors for PD include
a. exposure to pesticides.
b. drinking caffeinated beverages.
c. genetic mutations on chromosomes 2 and 8.
d. only genetic abnormalities.
4. Which symptom of PD has a diagnostic sensitivity of 99%?
a. intentional tremor
b. cogwheel rigidity
d. postural instability
5. Which nonmotor symptoms are associated with basal ganglia involvement?
a. mild dementia and psychosis
b. apathy, restlessness, and impulse control
c. depression, anxiety, and sleep disorders
d. orthostatic hypotension, constipation, and sensory disorders
6. Of the nonmotor symptoms, dysphagia usually
a. occurs late in PD disease progression.
b. occurs early in PD disease progression.
c. occurs before dysarthria.
d. is not associated with PD.
7. What percentage of PD patients has clinically significant depression?
8. When making a differential diagnosis, imaging tests can identify
c. multiple cerebral infarctions.
d. Alzheimer disease.
9. Which medication or drug category is most effective for managing PD symptoms?
c. dopamine agonists
10. Bromocriptine and pramipexole are examples of drugs from which category?
a. COMT inhibitors
c. MAO-B inhibitors
d. dopamine agonists
11. The action of the MAO-B inhibitor selegiline is to
a. stimulate the subthalamic nucleus.
b. stimulate dopamine receptors in the brain.
c. block proteins that inactivate dopamine.
d. block cholinesterase effects at the synapse.
12. What is the effect of anticholinergic drugs in treating PD?
a. decrease rigidity
b. reduce tremors
c. decrease “wearing off” periods
d. reduce incidence of dyskinesias
13. Because of adverse reactions, which antidepressant should be used cautiously in older patients with PD?
14. Adverse reactions to DBS include
a. risk of increasing “on-off time.”
b. risk of unintentional pallidotomy.
c. speech disorders and seizures.
d. stimulation of the subthalamic nucleus.
15. The authors advise using all these nonpharmacologic PD management strategies except
a. patient and family education.
b. cognitive stimulation exercises.
c. occupational and physical therapy.
d. support groups for the patient and family.
16. Which was not reported as research-based for reducing motor-related symptoms?
a. Tai Chi
17. Which organization developed the 10 Quality Measures for PD Improvement?
a. National Institutes of Health
b. Movement Disorder Society
c. Parkinson's Disease Association
d. American Academy of Neurology
18. What resource do the authors suggest for setting goals and advanced care planning?
a. Parkinson's Disease Model of Care
b. 10 Qualities for PD Improvement
c. Unified Parkinson Disease Rating Scale
d. Parkinson's Disease Common Data Elements Standards